Annals of Pharmacotherapy · 2022 · 12 citations · 19 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyDiagnostic MicrobiologyAntibacterial PharmacologyAntibiotic ResistanceAntimicrobial Susceptibility TestingDe-escalation Of Antimicrobial TherapyDrug EvaluationPneumonia PharmacotherapyAntibiotic Prescribing AlgorithmsDuration In Pneumonia TreatmentMethicillin-resistant Staphylococcus Aureus Infection TreatmentMethicillin-resistant Staphylococcus Aureus Pneumonia TreatmentMethicillin-resistant Staphylococcus Aureus TreatmentPositive Predictive ValuePrimary Outcome AnalysisRapid Antimicrobial Resistance Detection
Background: Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be detected using nasal swab polymerase chain reaction (PCR) assay and is associated with clinical MRSA infection. The MRSA nasal PCR has a rapid turnaround time and a negative predictive value for MRSA pneumonia of >98%; however, data are limited in critically ill patients. Objective: The purpose of this study is to determine the impact of a pharmacist-driven algorithm, utilizing MRSA PCR nasal screening on duration of anti-MRSA therapy in patients admitted to the intensive care unit (ICU) with suspected pneumonia. Methods: A single-center pre/post study was conducted in 4 ICUs at a large tertiary care community hospital. Adult patients admitted to the ICU initiated on vancomycin or linezolid for pneumonia managed using a pharmacist-driven MRSA PCR algorithm were included in the algorithm cohort. A historical cohort with standard management was matched 1:1 by age, type of pneumonia, and Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The primary outcome was duration of anti-MRSA therapy. Secondary outcomes included MRSA rates, number of vancomycin levels, new onset of acute kidney injury (AKI), ICU length of stay (LOS), hospital LOS, and mortality. Results: Of the 245 patients screened, 50 patients met inclusion criteria for the algorithm cohort and were matched to 50 patients in the historical cohort. The duration of anti-MRSA therapy was significantly lower compared with the historical cohort (47 vs 95 hours; P < 0.001). Secondary outcomes were similar between groups for MRSA rates, new onset of AKI, LOS, and mortality. There were less vancomycin levels ordered in the algorithm cohort (2 vs 3, P = 0.026). Conclusions: A pharmacist-driven MRSA PCR algorithm significantly reduced anti-MRSA duration of therapy in critically ill patients with pneumonia. Future studies should validate these results in critically ill populations and in settings where MRSA pneumonia is more prevalent.
19
André C. Kalil, Mark L. Metersky, Michael Klompas et al. · Clinical Infectious Diseases · 2016 · 3.9K citations · Full text
Joshua P. Metlay, Grant Waterer, Ann C. Long et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 3.6K citations · Full text
Michael J. Rybak, Jennifer Lê, Thomas P. Lodise et al. · American Journal of Health-System Pharmacy · 2020 · 1.1K citations · Full text
Kidney International Supplements · 2012 · 754 citations · Full text
Hematologic Effects of Linezolid: Summary of Clinical Experience
Stanton L. Gerson, Sheldon L. Kaplan, Jon Bruss et al. · Antimicrobial Agents and Chemotherapy · 2002 · 443 citations · Full text
Medicine, Hematology, Pharmacology +14